Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Applied Therapeutics ( (APLT) ).
Applied Therapeutics, Inc. has appointed John H. Johnson as Executive Chairman and Les Funtleyder as interim CEO, following the resignation of Dr. Shoshana Shendelman. The company is navigating regulatory challenges, having received a Complete Response Letter from the FDA and withdrawing a European MAA for govorestat, while planning to submit a new NDA for Sorbitol Dehydrogenase deficiency after Q1 2025.
More about Applied Therapeutics
Applied Therapeutics, Inc. operates in the pharmaceutical and biotechnology industry, focusing on the development and commercialization of drug therapies. The company is currently involved in programs addressing conditions such as Sorbitol Dehydrogenase deficiency and Classic Galactosemia.
YTD Price Performance: -69.55%
Average Trading Volume: 4,940,551
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $118.7M
For a thorough assessment of APLT stock, go to TipRanks’ Stock Analysis page.
